As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.» Read More
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
There's a lot of fear about Friday's jobs report. Bears are already saying this could be the report that finally forces the markets to take a breather.
U.S. stock index futures climbed Thursday as Wall Street cheered a better-than-expected jobless claims report and after the European Central Bank cut its key interest rate.
The Fed is expected to repeat its dovish message in the coming week, which could provide a safety net for the market amid a big wave of earnings and the April jobs report.
China is handling an outbreak of bird flu much better than in the past, Sanofi CEO Chris Viehbacher told CNBC on Thursday.
Sanofi CEO Chris Viehbacher shares his opinion on how China has handled recent bird flu concerns and what impact President Obama's budget might have on pharmaceuticals.
China said it was mobilizing resources nationwide to combat a new strain of bird flu that has killed six people, as Japan, Hong Kong and the United States stepped up vigilance.
A few health care stocks still hold potential, Orbimed Advisors Managing Partner Sam Isaly says.
Simon Grose-Hodge, Head of Investment Advisory, Singapore at LGT Bank talks Cyprus and tells CNBC's Cash which stocks will benefit from the weak euro.
These four biotech stocks could take a big hit when investors start to focus on lower-valued stocks in other industries. TheStreet.com reports.
Stocks finished slightly lower in lackluster trading Monday as investors remained cautious amid a lack of new market catalysts following the recent rally that helped the S&P 500 end its sixth-consecutive week higher.
Take a look at some of Monday midday movers:
European shares closed lower on Monday as sharp falls in Danish pharma group Novo Nordisk outweighed rallies in rival Sanofi and Dutch retailer Ahold.
Some of the names on the move ahead of the open.
U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
European shares closed lower after choppy trading on Thursday, tracking falls on the U.S. equity markets.
Christopher Viehbacher, CEO of Sanofi, pledges a different and radical approach to innovation.
Pfizer's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook.
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.